Fundamental research of host immune-genomics and development of new cancer therapy for ovarian cancer

• Project/Area Number: 26293359
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Partial Multi-year Fund
• Section: 一般
• Research Field: Obstetrics and gynecology
• Research Institution: Kyoto University
• Principal Investigator: Hamanishi Junzo 京都大学, 医学(系)研究科(研究院), 講師 (80378736)
• Co-Investigator(Kenkyū-buntansha): 松村 謙臣 京都大学, 医学(系)研究科(研究院), 准教授 (20452336) ; 安彦 郁 京都大学, 医学(系)研究科(研究院), 助教 (20508246) ; 小西 郁生 京都大学, 医学(系)研究科(研究院), 教授 (90192062)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥15,990,000 (Direct Cost: ¥12,300,000、Indirect Cost: ¥3,690,000); Fiscal Year 2016: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000); Fiscal Year 2015: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000); Fiscal Year 2014: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
• Keywords: がん免疫逃避 / Immuno-genomics / がん免疫療法 / 卵巣がん / 免疫チェックポイント阻害薬 / PD-L1 / PD-1 / 婦人科腫瘍学 / 腫瘍免疫 / 医療・福祉 / 癌 / 免疫学 / 腫瘍免疫学 / がん免疫逃避機構 / 卵巣癌 / 免疫ゲノミクス

Outline of Final Research Achievements

To investigate the host immune-genomics and development of new cancer therapy for ovarian cancer, we found several immunosuppression related genes in mouse ovarian cancer model with both or either of oncogenes and onco-suppressor genes transfected mouse ovarian cancer cell lines. And we found tumor antigen specific immunosuppressive genes by repeating injections OVA overexpressed ovarian cancer cell line. Lastly we could detect some immunosuppressive function of these genes in vitro and vivo mouse model and find a new potential target of ovarian cancer treatment.

Research Products

• [Journal Article] Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. (2016)
  • Author(s): Abou-Taleb H, Yamaguchi K, Matsumura N, Murakami R, Nakai H, Higasa K, Amano Y, Abiko K, Yoshioka Y, Hamanishi J, Koshiyama M, Baba T, Yamada R, Matsuda F, Konishi I, Mandai M.
  • Journal Title: Oncotarget. Volume: Aug 23;7(34) Issue: 34 Pages: 54758-54770
  • DOI: 10.18632/oncotarget.10181
  • NAID: 120005820857
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Immune checkpoint inhibition in ovarian cancer. (2016)
  • Author(s): Hamanishi J, Mandai M, Konishi I.
  • Journal Title: Int Immunol. Volume: 28 Issue: 7 Pages: 339-48
  • DOI: 10.1093/intimm/dxw020
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. (2016)
  • Author(s): Yamanoi K, Matsumura N, Murphy SK, Baba T, Abiko K, Hamanishi J, Yamaguchi K, Koshiyama M, Konishi I, Mandai M.
  • Journal Title: Oncotarget. Volume: Jul 26;7(30) Issue: 30 Pages: 47620-47636
  • DOI: 10.18632/oncotarget.9951
  • NAID: 120005820858
  • Peer Reviewed / Open Access / Int'l Joint Research
• [Journal Article] Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. (2016)
  • Author(s): Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I.
  • Journal Title: Int J Clin Oncol Volume: Jun;21(3) Issue: 3 Pages: 456-61
  • DOI: 10.1007/s10147-016-0968-y
  • Peer Reviewed
• [Journal Article] Dual faces of IFN-γ in cancer progression: a role of PD-L1 induction in the determination of pro- and anti-tumor immunity. (2016)
  • Author(s): Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I.
  • Journal Title: Clin Cancer Res Volume: May 15;22(10) Issue: 10 Pages: 2329-34
  • DOI: 10.1158/1078-0432.ccr-16-0224
  • Peer Reviewed
• [Journal Article] Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. (2016)
  • Author(s): Murakami R, Matsumura N, Brown JB, Wang Z, Yamaguchi K, Abiko K, Yoshioka Y, Hamanishi J, Baba T, Koshiyama M, Mandai M, Yamada R, Konishi I.
  • Journal Title: Gynecol Oncol. Volume: 141 Issue: 1 Pages: 49-56
  • DOI: 10.1016/j.ygyno.2016.02.027
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. (2016)
  • Author(s): Murakami R, Matsumura N, Mandai M, Yoshihara K, Tanabe H, Nakai H, Yamanoi K, Abiko K, Yoshioka Y, Hamanishi J, Yamaguchi K, Baba T, Koshiyama M, Enomoto T, Okamoto A, Murphy SK, Mori S, Mikami Y, Minamiguchi S, Konishi I
  • Journal Title: Am J Pathol. Volume: 186 Issue: 5 Pages: 1103-13
  • DOI: 10.1016/j.ajpath.2015.12.029
  • Peer Reviewed / Int'l Joint Research
• [Journal Article] 卵巣がんにおけるPD-1/PD-L1経路の解明と新規治療開発(原著論文) (2016)
  • Author(s): 濱西 潤三*
  • Journal Title: 日本産科婦人科学会雑誌 Volume: 68 Pages: 2696-2708
• [Journal Article] 新しい免疫療法の開発 PD-1抗体の臨床試験(解説) (2016)
  • Author(s): 濱西 潤三*
  • Journal Title: 日本外科学会雑誌 Volume: 117 Pages: 625-626
• [Journal Article] 先行する癌腫における治療成績 婦人科癌(解説/特集) (2016)
  • Author(s): 濱西 潤三*, 万代 昌紀, 小西 郁生
  • Journal Title: 肝・胆・膵 Volume: 73 Pages: 381-389
• [Journal Article] Dual faces of IFN-γ in cancer progression: a role of PD-L1 induction in the determination of pro- and anti-tumor immunity. (2016)
  • Author(s): Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I.
  • Journal Title: Clin Cancer Res. Volume: 未
  • Peer Reviewed
• [Journal Article] Anti-PD-L1/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. (2016)
  • Author(s): Mandai M, Hamanishi J, Abiko K, Matsumura N, Baba T, Konishi I.
  • Journal Title: Int J Clin Oncol. Volume: 未
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. (2016)
  • Author(s): Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I.
  • Journal Title: Int J Clin Oncol Volume: 未
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. (2015)
  • Author(s): Peng J, Hamanishi J, Matsumura N, Abiko K, Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, Konishi I, Mandai M.
  • Journal Title: Cancer Res. Volume: 75 Issue: 23 Pages: 5034-5045
  • DOI: 10.1158/0008-5472.can-14-3098
  • Peer Reviewed
• [Journal Article] Genomic profile predicts the efficacy of neoadjuvant chemotherapy for cervical cancer patients. (2015)
  • Author(s): Horikawa N, Baba T, Matsumura N, Murakami R, Abiko K, Hamanishi J, Yamaguchi K, Koshiyama M, Yoshioka Y, Konishi I.
  • Journal Title: BMC Cancer. Volume: 15 Pages: 739-739
  • NAID: 120005749961
  • Peer Reviewed
• [Journal Article] Safety and Anti-tumor Activity of Anti–PD-1 Antibody (Nivolumab: ONO-4538/BMS-936558) in Patients with Platinum-resistant Ovarian Cancer. (2015)
  • Author(s): Hamanishi, J., M. Mandai, T. Ikeda, M. Minami, A. Kawaguchi, T. Murayama, M. Kanai, Y. Mori, S. Matsumoto, S. Chikuma, N. Matsumura, K. Abiko, T. Baba, K. Yamaguchi, A. Ueda, Y. Hosoe, S. Morita, M. Yokode, A. Shimizu, T. Honjo, I. Konishi.
  • Journal Title: J Clin Oncol Volume: 33 Issue: 34 Pages: 4015-22
  • DOI: 10.1200/jco.2015.62.3397
  • Peer Reviewed / Open Access
• [Journal Article] Metabolic alterations caused by HNF1β expression in ovarian clear cell carcinoma contribute to cell survival. (2015)
  • Author(s): Amano Y, Mandai M, Yamaguchi K, Matsumura N, Kharma B, Baba T, Abiko K, Hamanishi J, Yoshioka Y, Konishi I.
  • Journal Title: Oncotarget. Volume: 6 Pages: 6-6
  • Peer Reviewed
• [Journal Article] 【最新 がん免疫療法 抗PD-1抗体、CAR-T細胞療法から、Neoantigenを標的としたがん制御機構まで】 免疫チェックポイントの基礎とがん免疫療法への開発 (2015)
  • Author(s): 濱西 潤三, 万代 昌紀, 小西 郁生
  • Journal Title: 実験医学 Volume: 33 Pages: 2193-2200
  • Peer Reviewed
• [Journal Article] 【新たな時代を迎えたがん免疫療法】 免疫チェックポイント阻害療法の現状と展望(解説/特集) (2015)
  • Author(s): 濱西 潤三, 万代 昌紀, 小西 郁生
  • Journal Title: Medical Science Digest Volume: 41 Pages: 287-290
• [Journal Article] 【女性がん医療の最前線】卵巣癌治療 (2015)
  • Author(s): 濱西 潤三, 万代 昌紀, 小西 郁生
  • Journal Title: Bio Clinica Volume: 16 Pages: 28-32
• [Journal Article] 【婦人科がん・泌尿器科がん】卵巣がんに対する免疫チェックポイントシグナル阻害薬の臨床応用 (2015)
  • Author(s): 濱西 潤三, 万代 昌紀, 小西 郁生
  • Journal Title: 腫瘍内科 Volume: 16 Pages: 121-127
• [Journal Article] 【新たな抗体治療の展開】 新たに開発された抗体治療 卵巣がん (2015)
  • Author(s): 濱西 潤三, 小西 郁生
  • Journal Title: がん分子標的治療 Volume: 13 Pages: 203-211
• [Journal Article] IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer (2015)
  • Author(s): Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M
  • Journal Title: British Journal of Cancer Volume: 未確定 Issue: 9 Pages: 1501-1509
  • DOI: 10.1038/bjc.2015.101
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] The BMP signaling pathway leads to enhanced proliferation in serous ovarian cancer-a potential therapeutic target. (2015)
  • Author(s): Peng J, Yoshioka Y, Mandai M, et al
  • Journal Title: Mol Carcinog Volume: Epub ahead of print Issue: 4 Pages: 1-11
  • DOI: 10.1002/mc.22283
  • Peer Reviewed / Open Access
• [Journal Article] Invasion of uterine cervical squamous cell carcinoma cells is facilitated by locoregional interaction with cancer-associated fibroblasts via activating transforming growth factor-beta. (2015)
  • Author(s): Nagura M, Matsumura N, Baba T, Murakami R, Kharma B, Hamanishi J, Yamaguchi K, Abiko K, Koshiyama M, Mandai M, Murata T, Murphy SK, Konishi I.
  • Journal Title: Gynecol Oncol. Volume: 136 Pages: 104-111
  • Peer Reviewed
• [Journal Article] Menstrual cyclic change of metastin/GPR54 in endometrium. (2015)
  • Author(s): Baba T, Kang HS, Hosoe Y, Kharma B, Abiko K, Matsumura N, Hamanishi J, Yamaguchi K, Yoshioka Y, Koshiyama M, Mandai M, Murphy SK, Konishi I.
  • Journal Title: Med Mol Morphol. Volume: 未定
  • Peer Reviewed
• [Journal Article] 話題の疾患と治療 免疫チェックポイントPD-1経路を標的とするがん治療への臨床応用(解説) (2015)
  • Author(s): 濱西 潤三, 万代 昌紀, 小西 郁生
  • Journal Title: 感染・炎症・免疫 Volume: 44 Pages: 387-389
• [Journal Article] Clinical approaches to treating papillary squamous cell carcinoma of the uterine cervix. (2014)
  • Author(s): Nagura M, Koshiyama M, Matsumura N, Kido A, Baba T, Abiko K, Hamanishi J, Yamaguchi K, Mikami Y, Konishi I.
  • Journal Title: BMC Cancer Volume: 14 Issue: 1 Pages: 784-784
  • DOI: 10.1186/1471-2407-14-784
  • Peer Reviewed / Open Access
• [Journal Article] STAT1 drives tumor progression in serous papillary endometrial cancer. (2014)
  • Author(s): Kharma B, Baba T, Matsumura N, Kang HS, Hamanishi J, Murakami R, McConechy MM, Leung S, Yamaguchi K, Hosoe Y, Yoshioka Y, Murphy SK, Mandai M, Huntsman DG, Konishi I.
  • Journal Title: Cancer Res. Volume: 74 Issue: 22 Pages: 6519-6530
  • DOI: 10.1158/0008-5472.can-14-0847
  • Peer Reviewed / Open Access
• [Journal Article] 難治性卵巣癌の克服を目指して 化学療法抵抗性卵巣癌の局所免疫の解析に基づいた、がん免疫逃避を標的とした新規治療戦略（第53回日本産科婦人科学会 学術集会 シンポジウム腫瘍） (2014)
  • Author(s): 濵西潤三
  • Journal Title: 日本産科婦人科学会雑誌 Volume: 66 Pages: 2777-2791
• [Journal Article] 【新たながん治療戦略の鍵を握るPD-1抗体:がん免疫療法が、がんを制する】PD-1抗体の臨床 進行卵巣がんに対する抗PD-1抗体療法(解説/特集) (2014)
  • Author(s): 濱西 潤三, 万代 昌紀, 小西 郁生
  • Journal Title: 細胞工学 Volume: 33 Pages: 1057-1060
• [Journal Article] 【がん免疫抑制・免疫疲弊と新規治療】 免疫チェックポイントPD-1/PD-L1経路を標的とする新しいがん治療(解説/特集) (2014)
  • Author(s): 濱西 潤三*, 小西 郁生
  • Journal Title: 癌と化学療法 Volume: 41 Pages: 1071-1076
• [Journal Article] 【がん免疫療法の進歩】 Immune-checkpoint阻害によるがん免疫療法(解説/特集) (2014)
  • Author(s): 濱西 潤三
  • Journal Title: 細胞 Volume: 46 Pages: 405-408
• [Journal Article] 卵巣癌のMolecular Medicine 遺伝子発現解析に基づく卵巣癌の薬剤選択を目指して(解説) (2014)
  • Author(s): 松村 謙臣, 村上 隆介, 山ノ井 康二, 山村 省吾, 山口 建, 濱西 潤三, 吉岡 弓子, 馬場 長, 森 誠一, 小西 郁生, 万代 昌紀
  • Journal Title: 日本婦人科腫瘍学会雑誌 Volume: 32 Pages: 203-210
• [Presentation] PD-1 signal blockade for ovarian cancer: Perspectives and issues. (2017)
  • Author(s): Hamanishi.J
  • Organizer: The 1st J-K-T Joint Conference of Obstetrics and Gynecology The 56th Annual Congress of Taiwan Association of Obstetrics and Gynecology
  • Place of Presentation: Taipei
  • Int'l Joint Research / Invited
• [Presentation] Specific gene signatures and oligoclonal expansion of B cell repertoire with the responders of anti-PD-1 antibody (Nivolumab) for ovarian cancer; (2016)
  • Author(s): Hamanishi J. Murakami R, Mandai M, Matsumura N, Abiko K, Baba T, Yamaguchi K, Konishi I.
  • Organizer: vASCO 2016 (The 52nd Annual Meeting of American Society of Clinical Oncology)
  • Place of Presentation: Chicago, IL. USA.
  • Year and Date: 2016-06-03
  • Int'l Joint Research
• [Presentation] 京都府内の専門医によるがん診療の最前線「新しいがん免疫療法（PD-1経路阻害薬）とは？ その期待と課題」 (2016)
  • Author(s): 濵西 潤三
  • Organizer: 府民公開講座
  • Place of Presentation: 京都府立医科大学図書館ホール(京都市)
  • Year and Date: 2016-03-05
  • Invited
• [Presentation] Use of Immunotherapy in platinum-resistant ovarian cancer (2016)
  • Author(s): Junzo Hamanshi
  • Organizer: Asian Oncology Summit 2016
  • Place of Presentation: ウエスティン都ホテル京都(京都市)
  • Year and Date: 2016-03-03
  • Int'l Joint Research / Invited
• [Presentation] シンポジウム 免疫が変える“がん治療の世界” 抗PD-1抗体 nivolumab を用いた卵巣がん治療への挑戦」 (2016)
  • Author(s): 濵西 潤三
  • Organizer: 第13回 日本免疫治療学研究会学術集会
  • Place of Presentation: 東京ガーデンパレス(東京都文京区)
  • Year and Date: 2016-02-27
  • Invited
• [Presentation] 卵巣がんに対する抗PD-1抗体（ニボルマブ）の有効性と安全性 (2016)
  • Author(s): 濵西 潤三
  • Organizer: 大阪婦人科腫瘍研究会
  • Place of Presentation: ハービスプラザ会議室(大阪市)
  • Year and Date: 2016-01-29
  • Invited
• [Presentation] 卒後教育セミナー「新しい免疫療法の開発～ 抗PD-1 抗体の臨床試験 ～」 (2016)
  • Author(s): 濵西潤三
  • Organizer: 第116 回日本外科学会学術集会
  • Place of Presentation: 大阪
  • Invited
• [Presentation] 学術奨励賞受賞講演「卵巣癌におけるPD-1/PD-L1経路の解明と新規治療開発」 (2016)
  • Author(s): 濵西潤三
  • Organizer: 第68回 日本産科婦人科学会
  • Place of Presentation: 東京
• [Presentation] Combining chemotherapy, targeted agents and radiotherapy with immunotherapy (2016)
  • Author(s): 濵西潤三
  • Organizer: GAP (Global Academic Programs of MD Anderson Cancer Center) 2016
  • Place of Presentation: Sao Paulo. Brazil
  • Int'l Joint Research / Invited
• [Presentation] PD-1経路阻害薬の今後の展望と課題：卵巣がん (2016)
  • Author(s): 濵西潤三
  • Organizer: 第20回日本がん分子標的治療学会学術集会
  • Place of Presentation: 別府市
  • Invited
• [Presentation] 卵巣がんホルマリン固定組織由来の超微量RNAを用いたシークエンスの可能性 (2016)
  • Author(s): 濵西潤三
  • Organizer: イルミナゲノムサミット2016
  • Place of Presentation: 東京
  • Invited
• [Presentation] シンポジウム「免疫チェックポイントPD-1経路阻害薬の展望」 (2016)
  • Author(s): 濵西潤三
  • Organizer: 第26回 日本サイトメトリー学会学術集会
  • Place of Presentation: 福岡市
  • Invited
• [Presentation] シンポジウム英語口演1 “PD-1 signal inhibitors :Future perspectives and Issues” (2016)
  • Author(s): Hamanishi J
  • Organizer: JSMO 2016 (The 24th Annual Meeting of Japanese Society of Medical Oncology).
  • Place of Presentation: Kobe
  • Invited
• [Presentation] シンポジウム英語口演2 “PD-1 signal inhibitors for ovarian cancer :Perspectives and Issues” (2016)
  • Author(s): Hamanishi J.
  • Organizer: JSMO 2016 (The 24th Annual Meeting of Japanese Society of Medical Oncology).
  • Place of Presentation: Kobe
  • Invited
• [Presentation] 特別講演「婦人科癌に対する免疫療法」 (2016)
  • Author(s): 濵西潤三
  • Organizer: Chugai Gynecologic Cancer Forum in Tokyo
  • Place of Presentation: 東京
  • Invited
• [Presentation] Specific gene signatures and oligo-clonal expansion of B cell repertoire with responders of anti-PD-1 antibody (Nivolumab) for ovarian cancer; Novel predictive biomarkers (2016)
  • Author(s): Hamanishi J. Murakami R, Mandai M, Matsumura N, Abiko K, Baba T, Yamaguchi K, Konishi I.
  • Organizer: The 75th Annual Meeting of Japanese Cancer Association (JCA).
  • Place of Presentation: Yokohama.
• [Presentation] シンポジウム「プラチナ抵抗性卵巣がんに対する抗PD-1抗体(Nivolumab)の有効性と安全性」 (2016)
  • Author(s): 濵西潤三
  • Organizer: 第54回 日本癌治療学会学術集会 Best of Cancer Investigation (Clinical Research)
  • Place of Presentation: Yokohama.
• [Presentation] 特別講演「卵巣がんに対する新規がん免疫治療への挑戦」 (2016)
  • Author(s): 濵西潤三
  • Organizer: 第9回 奈良婦人科腫瘍カンファランス
  • Place of Presentation: 奈良
  • Invited
• [Presentation] 招待講演「卵巣がんに対する新規がん免疫治療への挑戦」 (2016)
  • Author(s): 濵西潤三
  • Organizer: AMED（日本医療研究開発機構）創薬等支援技術基盤等プラットフォーム 第12回制御拠点協議会
  • Place of Presentation: 京都
  • Invited
• [Presentation] 招請講演「免疫チェックポイント阻害薬」 (2016)
  • Author(s): 濵西潤三
  • Organizer: AMED（日本医療研究開発機構）第4回創薬等支援技術基盤プラットフォーム公開シンポジウム
  • Place of Presentation: 東京
  • Invited
• [Presentation] Evaluating the Potential of Immune Checkpoint Inhibitors in Ovarian Cancer (2015)
  • Author(s): Junzo Hamanshi
  • Organizer: ESMO Asia 2015 Expert Panel (Invited Oral)
  • Place of Presentation: Suntec City.Singapore
  • Year and Date: 2015-12-18
  • Int'l Joint Research / Invited
• [Presentation] Immunotherapy for gynecological cancers: Challenges and opportunities (2015)
  • Author(s): Junzo Hamanshi
  • Organizer: ESMO Asia 2015. Precision medicine and developmental therapeutics in gynaecologic oncology (Special Symposium)
  • Place of Presentation: Suntec City.Singapore
  • Year and Date: 2015-12-18
  • Int'l Joint Research / Invited
• [Presentation] 卵巣がんに対する新しい治療戦略 (2015)
  • Author(s): 濵西 潤三
  • Organizer: がん化学療法地域連携セミナー
  • Place of Presentation: 大阪赤十字病院(大阪市)
  • Year and Date: 2015-12-15
  • Invited
• [Presentation] The challenges and opportunities on the novel anti-tumor treatment with PD-1 signal blockade -Investigator initiated clinical trial of Nivolumab for platinum-resistant ovarian cancer - (2015)
  • Author(s): Junzo Hamanshi
  • Organizer: Japan Sarcoma Association Symposium SYMPOSIUM
  • Place of Presentation: 京都平安ホテル(京都市)
  • Year and Date: 2015-12-03
  • Invited
• [Presentation] 卵巣がんに対する新しい治療戦略：PD-1/PD-L1経路阻害薬 (2015)
  • Author(s): 濵西 潤三
  • Organizer: 第30回 日本生殖免疫学会 学術集会 ワークショップ指定演題
  • Place of Presentation: 熊本県民交流館パレア(熊本市)
  • Year and Date: 2015-11-22
  • Invited
• [Presentation] Clinical impact of anti-PD-1 antibody (Nivolumab) for platinum-resistant ovarian cancer; Investigator initiated phase II clinical trial (2015)
  • Author(s): Hamanishi J, Mandai M, Matsumura N, Abiko K, Yamaguchi K, Baba T, Konishi I
  • Organizer: The 4th Biennial Meeting of Asian Society of Gynecologic Oncology
  • Place of Presentation: Seoul, Korea.
  • Year and Date: 2015-11-13
  • Int'l Joint Research
• [Presentation] 卵巣癌の微小免疫環境解析と抗PD-1抗体療法の展望 (2015)
  • Author(s): 濱西 潤三、万代 昌紀、松村 謙臣、安彦 郁、村上 隆介、馬場 長、山口 建、小西郁生
  • Organizer: 第53回日本癌治療学会学術集会 臓器別シンポジウム
  • Place of Presentation: 国立京都国際会館(京都市)
  • Year and Date: 2015-10-30
  • Invited
• [Presentation] Chemoimmunotherapy with PD-1 blockade and paclitaxel induce a potent antitumor immunity in ovarian cancers (2015)
  • Author(s): Hamanishi J, Peng J, Matsumura N. Abiko K, , Baba T, Yamaguchi K, Hosoe Y, Konishi I, Mandai M,
  • Organizer: Advances in Ovarian Cancer Research: Exploiting Vulnerabilities
  • Place of Presentation: Orlando, USA
  • Year and Date: 2015-10-17
  • Int'l Joint Research
• [Presentation] 免疫チェックポイントPD-1/PD-L1経路を標的とする新しいがん治療 (2015)
  • Author(s): 濵西 潤三
  • Organizer: 第7回 埼玉南西部地区がん化学療法研究会
  • Place of Presentation: 埼玉
  • Year and Date: 2015-10-10
  • Invited
• [Presentation] 卵巣癌に対するニボルマブ（抗PD-1抗体）を用いた新規がん治療薬の医師主導第2相治験 (2015)
  • Author(s): 濵西 潤三
  • Organizer: 京都大学大学院 教育コース「臨床研究」コース （招請講演）
  • Place of Presentation: 京都大学(京都市)
  • Year and Date: 2015-10-10
  • Invited
• [Presentation] Survival and Durable Tumor Remission for platinum-resistant Ovarian Cancer receiving Nivolumab (anti-PD-1 antibody). (2015)
  • Author(s): Hamanishi J, Mandai M, Matsumura N. Abiko K, Peng J, Horikawa N, Baba T, Yamaguchi K, Hosoe Y, Konishi I.
  • Organizer: The 74rd Annual Meeting of Japan Cancer Association, International Session
  • Place of Presentation: 名古屋国際会議場(名古屋市)
  • Year and Date: 2015-10-08
  • Invited
• [Presentation] 卵巣癌に対する免疫チェックポイント阻害薬 抗PD-1抗体の臨床応用 (2015)
  • Author(s): 濵西潤三
  • Organizer: 第57回日本婦人科腫瘍学会学術集会 「教育シンポジウム3」Immuno Oncology
  • Place of Presentation: アイーナ岩手県民情報センター(盛岡市)
  • Year and Date: 2015-08-08
  • Invited
• [Presentation] 抗PD-1抗体を用いた新しいがん免疫治療～卵巣癌に対する医師主導第II相治験を通して～ (2015)
  • Author(s): 濵西潤三
  • Organizer: 第11回 大阪小児固形腫瘍研究会 （招待講演）
  • Place of Presentation: 大阪大学医学部附属病院(大阪市)
  • Year and Date: 2015-06-05
  • Int'l Joint Research / Invited
• [Presentation] Durable Tumor Remission in Patients with Platinum-Resistant Ovarian Cancer Receiving Nivolumab (2015)
  • Author(s): Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Shimizu A, Honjo T, Konishi I.
  • Organizer: The 51th Annual meeting of American Society of Clinical Oncology (ASCO)
  • Place of Presentation: Chicago USA.
  • Year and Date: 2015-05-30
  • Int'l Joint Research
• [Presentation] がん治療のパラダイムシフト ～免疫チェックポイントPD-1経路を標的とした (2015)
  • Author(s): 濵西潤三
  • Organizer: 北関東婦人科化学療法講演会2015
  • Place of Presentation: TKP東京駅前カンファレンスセンター(東京都千代田区)
  • Year and Date: 2015-04-24
  • Invited
• [Presentation] The Next Generation of Cancer Immunotherapy "Immune Checkpoint PD-1 signal blocking for Ovarian Cancer (2015)
  • Author(s): Hamanishi J
  • Organizer: Seminar for Cancer Course Kyoto University 2015
  • Place of Presentation: 京都大学(京都市)
  • Year and Date: 2015-04-23
  • Invited
• [Presentation] 「抗PD 1 抗体（Nivolumab）を用いた卵巣癌に対する第II 相医師主導治験」 (2015)
  • Author(s): 濵西潤三、万代昌紀、松村謙臣、安彦郁、馬場長、山口建、植田彰彦、小西郁生
  • Organizer: 第67回 日本産科婦人科学会学術集会 （優秀演題賞受賞講演）
  • Place of Presentation: パシフィコ横浜(横浜市)
  • Year and Date: 2015-04-10
  • Invited
• [Presentation] Durable anti-tumor response of Nivolumab (anti-PD-1 antibody) for platinum-resistant ovarian cancer; phase II clinical trial <Scientific Plenary> (2015)
  • Author(s): Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Yamaguchi K, Konishi I
  • Organizer: Annual Meeting on Woman’s Cancer
  • Place of Presentation: Chicago
  • Year and Date: 2015-03-31
• [Presentation] 文部科学省 橋渡し研究加速ネットワーク～抗PD-1抗体（Nivolumab）を用いたプラチナ抵抗性再発・進行卵巣癌に対する治療効果と安全性の評価～ (2015)
  • Author(s): 濱西潤三、清水章, 池田隆文
  • Organizer: 文部科学省・厚生労働省 革新的医療技術創出拠点プロジェクト 「医療イノベーション創出ネットワークの現状と展望―新しいフェーズに入ったアカデミアのシーズ開発」平成26年度成果報告会
  • Place of Presentation: 東京コンベンションセンター
  • Year and Date: 2015-03-05
• [Presentation] 府民公開講座 京都府内の専門医によるがん診療の最前線 (2015)
  • Author(s): 濵西 潤三
  • Organizer: 府民公開講座
  • Place of Presentation: 京都府立医科大学図書館ホール
  • Year and Date: 2015-02-22
  • Invited
• [Presentation] 抗PD-1抗体（Nivolumab）を用いたあたらしいがん治療 (2015)
  • Author(s): 濵西 潤三
  • Organizer: The 10th Kyoto Hematology Forum
  • Place of Presentation: ウェスティン都ホテル京都
  • Year and Date: 2015-02-21
  • Invited
• [Presentation] 卵巣癌に対する抗PD-1抗体を用いた医師主導第II相治験 (2015)
  • Author(s): 濵西 潤三
  • Organizer: がんプロフェッショナル養成基盤推進プラン 第3回 トランスレーショナルリサーチシンポジウム「がん免疫療法の最前線」
  • Place of Presentation: 慶応義塾大学
  • Year and Date: 2015-02-14
  • Invited
• [Presentation] Immunotherapy with anti-PD-1 antibody (Nivolumab) is promising: Phase II trial for platinum-resistant ovarian cancer (2014)
  • Author(s): Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Jin Peng, Naoki Horikawa, Kumuruz Murat, Tsukasa Baba, Ken Yamaguchi, Ikuo Konishi
  • Organizer: 第43回日本免疫学会学術集会 The 43rd JSI Workshop
  • Place of Presentation: 京都国際会館
  • Year and Date: 2014-12-11
• [Presentation] 免疫チェックポイントPD-1経路を標的とした 新しいがん治療 (2014)
  • Author(s): 濵西 潤三
  • Organizer: 第11回 がんワクチン療法研究会学術集会 特別講演
  • Place of Presentation: 東京女子医大
  • Year and Date: 2014-11-22
  • Invited
• [Presentation] A Phase II Clinical Trial of Immunotherapy with Anti-PD-1 Antibody (Nivolumab) in Advanced/Relapsed, Platinum-resistant Ovarian Cancer (2014)
  • Author(s): Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Jin Peng, Naoki Horikawa, Tsukasa Baba, Ken Yamaguchi, Ikuo Konishi
  • Organizer: 15th Biennial Meeting of The International Gynecological Cancer Society
  • Place of Presentation: Melbourne Australia
  • Year and Date: 2014-11-08
• [Presentation] 『がんへの挑戦～京都大学の取組み～』世界が注目！ (2014)
  • Author(s): 濱西潤三
  • Organizer: 市民公開講座
  • Place of Presentation: 京都大学
  • Year and Date: 2014-10-19
  • Invited
• [Presentation] Immune checkpoint PD-1 signal: the metastatic promotion of ovarian cancer and the target of new treatment strategy (2014)
  • Author(s): Junzo Hamanishi, Masaki Mandai, Noriomi Matsumura, Kaoru Abiko, Jin Peng, Naoki Horikawa, Tsukasa Baba, Ken Yamaguchi, Ikuo Konishi
  • Organizer: 第73回日本癌学会学術集会 シンポジウム The 73rd JCA Symposia
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2014-09-27
• [Presentation] がん治療のパラダイムシフト ～抗PD-1抗体（Nivolumab）を用いた卵巣癌への挑戦～ (2014)
  • Author(s): 濵西潤三
  • Organizer: 平成26年度 一土会講演会 特別講演
  • Place of Presentation: ホテルアソシア静岡
  • Year and Date: 2014-09-03
  • Invited
• [Presentation] 抗PD-1抗体（Nivolumab）を用いた卵巣癌に対する第II相医師主導治験 （最優秀演題賞受賞講演）） (2014)
  • Author(s): 濵西潤三、万代昌紀、池田隆文、南 学、森由紀子、松本繁巳、竹馬俊介、村山 敏典、松村謙臣、安彦郁、山口建、植田彰彦、森田智視、清水章、本庶佑、小西郁生
  • Organizer: 第52回 日本癌治療学会学術集会
  • Place of Presentation: パシフィコ横浜
  • Year and Date: 2014-08-29
• [Presentation] Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer (2014)
  • Author(s): Junzo Hamanishi, Masaki Mandai*, Takafumi Ikeda, Manabu Minami, Atsushi Kawaguchi, , Masashi Kanai, Yukiko Mori, Shigemi Matsumoto, Toshinori Murayama, Shunsuke Chikuma, Noriomi Matsumura, Kaoru Abiko, Tsukasa Baba, Ken Yamaguchi, Akihiko Ueda, Satoshi Morita, Masayuki Yokode, Akira Shimizu, Tasuku Honjo, Ikuo Konishi
  • Organizer: The 50th Annual meeting of American Society of Clinical Oncology (ASCO2014)
  • Place of Presentation: Chicago
  • Year and Date: 2014-06-01
• [Presentation] シンポジウム：腫瘍 難治性卵巣癌の克服を目指して 化学療法抵抗性卵巣癌の局所免疫の解析に基づいたがん免疫逃避を標的とした新規治療戦略 (2014)
  • Author(s): 濵西 潤三
  • Organizer: 第66回 日本産科婦人科学会学術講演会
  • Place of Presentation: 東京国際フォーラム
  • Year and Date: 2014-04-19
• [Book] 次世代のがん治療薬・診断のための研究開発 ～免疫療法・遺伝子治療・がん幹細胞～ (2016)
  • Author(s): 濱西潤三
  • Total Pages: 400
  • Publisher: 技術情報協会
• [Book] 卵巣癌におけるがん免疫療法- Immuno-Oncology Up to date - (2016)
  • Author(s): 濱西潤三、万代昌紀、小西郁生
  • Total Pages: 224
  • Publisher: メディカルレビュー社 がん免疫療法ハンドブック 第１版
• [Remarks] 京都大学産婦人科 ホームページ
  • URL: http://www.kuhp.kyoto-u.ac.jp/~obgy/
• [Remarks] 京都大学医学部附属病院 産科婦人科 ホームページ
  • URL: http://www.kuhp.kyoto-u.ac.jp/~obgy/